Apoptotic and anti-Warburg effect of Morusin via ROS mediated inhibition of FOXM1/c-Myc signaling in prostate cancer cells.

Though Morusin is known to induce apoptotic, antiprolifertaive, and autophagic effects through several signaling pathways, the underlying molecular mechanisms of Morusin still remain unclear until now. To elucidate antitumor mechanism of Morusin, cytotoxicity assay, cell cycle analysis, Western blotting, TUNEL assay, RNA interference, immunofluorescense, immunoprecipitation, reactive oxygen species (ROS) measurement, and inhibitor study were applied in this study. Morusin enhanced cytotoxicity, increased the number of TUNEL positive cells, sub-G1 population and induced the cleavages of PARP and caspase3, attenuated the expression of HK2, PKM2, LDH, c-Myc, and Forkhead Box M1 (FOXM1) along with the reduction of glucose, lactate, and ATP in DU145 and PC3 cells. Furthermore, Morusin disrupted the binding of c-Myc and FOXM1 in PC-3 cells, which was supported by String and cBioportal database. Notably, Morusin induced c-Myc degradation mediated by FBW7 and suppressed c-Myc stability in PC3 cells exposed to MG132 and cycloheximide. Also, Morusin generated ROS, while NAC disrupted the capacity of Morusin to reduce the expression of FOXM1, c-Myc, pro-PARP, and pro-caspase3 in PC-3 cells. Taken together, these findings provide scientific evidence that ROS mediated inhibition of FOXM1/c-Myc signaling axis plays a critical role in Morusin induced apoptotic and anti-Warburg effect in prostate cancer cells. Our findings support scientific evidence that ROS mediated inhibition of FOXM1/c-Myc signaling axis is critically involved in apoptotic and anti-Warburg effect of Morusin in prostate cancer cells.

[1]  Sung-Hoon Kim,et al.  Antitumor Effect of Morusin via G1 Arrest and Antiglycolysis by AMPK Activation in Hepatocellular Cancer , 2021, International journal of molecular sciences.

[2]  Sung-Hoon Kim,et al.  UBE2M Drives Hepatocellular Cancer Progression as a p53 Negative Regulator by Binding to MDM2 and Ribosomal Protein L11 , 2021, Cancers.

[3]  M. Ye,et al.  Morusin inhibits the growth of human colorectal cancer HCT116-derived sphere-forming cells via the inactivation of Akt pathway , 2021, International journal of molecular medicine.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  E. Tsiani,et al.  Curcumin against Prostate Cancer: Current Evidence , 2020, Biomolecules.

[6]  Guoyi Jiang,et al.  FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7. , 2020, Gene.

[7]  Hyun-Ji Park,et al.  Induction of cytoprotective autophagy by morusin via AMP-activated protein kinase activation in human non-small cell lung cancer cells , 2020, Nutrition research and practice.

[8]  Q. Yin,et al.  Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2 , 2019, IUBMB life.

[9]  K. Sai,et al.  R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells , 2019, Cell Death & Disease.

[10]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[11]  Jung,et al.  p53-Dependent Apoptotic Effect of Puromycin via Binding of Ribosomal Protein L5 and L11 to MDM2 and Its Combination Effect with RITA or Doxorubicin , 2019, Cancers.

[12]  K. Mansouri,et al.  Cancer cells change their glucose metabolism to overcome increased ROS: One step from cancer cell to cancer stem cell? , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  P. Kantoff,et al.  Treatment of Advanced Prostate Cancer. , 2019, Annual review of medicine.

[14]  Sung-Hoon Kim,et al.  Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA‐MB231 breast cancer cells , 2018, Phytotherapy research : PTR.

[15]  X. Zou,et al.  Metformin facilitates BG45‑induced apoptosis via an anti‑Warburg effect in cholangiocarcinoma cells. , 2018, Oncology reports.

[16]  Wei Wei,et al.  Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer , 2018, World Journal of Surgical Oncology.

[17]  X. Lv,et al.  Morusin induces paraptosis-like cell death through mitochondrial calcium overload and dysfunction in epithelial ovarian cancer. , 2018, Chemico-biological interactions.

[18]  Feng Wang,et al.  Morusin inhibits cell proliferation and tumor growth by down-regulating c-Myc in human gastric cancer , 2017, Oncotarget.

[19]  Howard H. Yang,et al.  The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis , 2016, Clinical Epigenetics.

[20]  K. Ahn,et al.  Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. , 2016, Journal of natural products.

[21]  N. Xing,et al.  Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (Review). , 2015, Oncology reports.

[22]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[23]  Soo-Jin Jeong,et al.  Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. , 2010, Biological & pharmaceutical bulletin.

[24]  G. Haas,et al.  The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. , 2008, The Canadian journal of urology.

[25]  Sangtaek Oh,et al.  Decursin Suppresses Human Androgen-Independent PC3 Prostate Cancer Cell Proliferation by Promoting the Degradation of β-Catenin , 2007, Molecular Pharmacology.

[26]  K. Ahn,et al.  Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. , 2015, American journal of cancer research.

[27]  E. Lam,et al.  FOXM1: From cancer initiation to progression and treatment. , 2012, Biochimica et biophysica acta.